Health & Environmental Research Online (HERO)


Print Feedback Export to File
7046420 
Journal Article 
Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study 
Bourne, RRA; Kaarniranta, K; Lorenz, K; Traverso, CE; Vuorinen, J; Ropo, A; , 
2019 
BMJ Open
EISSN: 2044-6055 
BMJ PUBLISHING GROUP 
LONDON 
English 
Bimatoprost-timolol (bimatoprost 0.03%-timolol 0.5% fixed-dose combination [FDC]) and tafluprost-timolol (tafluprost 0.0015%-timolol 0.5% FDC) eye drops are currently the only topical intraocular pressure (IOP)-reducing therapies available as preservative-free (PF) prostaglandin and timolol FDC. The aim of this study was to investigate changes to ocular signs and symptoms when patients with ocular hypertension (OH) or open-angle glaucoma (OAG) switched from PF or benzalkonium chloride (BAK)-preserved bimatoprost-timolol to PF tafluprost-timolol eye drops. 
• PFAS Universe
     Data Source
          Web of Science
     Perflunafene